Risk-based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group.

Leo MascarenhasElizabeth R LydenPhilip P BreitfeldDavid O WalterhouseSarah S DonaldsonDavid A RodebergDavid M ParhamJames R AndersonWilliam H MeyerDouglas S Hawkins

Published in: Cancer (2019)

Patients with UR RMS at first relapse or disease progression have a poor prognosis when they are treated with this multi-agent therapy, whereas FR patients have a higher chance of being cured with second-line therapy.

Keyphrases

poor prognosis
end stage renal disease
long non coding rna
newly diagnosed
ejection fraction
chronic kidney disease
young adults
palliative care
free survival
peritoneal dialysis
stem cells
smoking cessation
patient reported